Immunomic Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Lancaster PA United States (2005)

Organization Overview

First Clinical Trial
2012
NCT01707069
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Immunomic Therapeutics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Rhinitis, Allergic, Seasonal (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 6